Media OutReach
BeOne Medicines Recognized as “Outstanding Global Oncology Company of the Year” at HKCT Business Awards 2026
Richard Cheng, Associate Commercial Director (Hong Kong & Macau) at BeOne, said: “We are honored to receive this award from the Hong Kong Commercial Times. BeOne has built differentiated capabilities across clinical development and manufacturing, supported by a broad and diverse R&D pipeline. In Hong Kong, we have introduced several therapies, including BTK, PD-1 and IL-6 inhibitors. Looking ahead, we will continue to advance our plans in Hong Kong by leveraging opportunities enabled by the ‘1+’ policy and the planned establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) and its ‘primary evaluation’ mechanism. Supported by our global supply network, we aim to bring additional medicines to patients in Hong Kong and the Greater Bay Area and help improve access to treatments aligned with international standards.”
Global R&D and Innovation
Founded in 2010, BeOne is focused on accelerating key stages of oncology innovation—from discovery through development to patient access. Through an integrated model spanning R&D, manufacturing and commercialization, the company works to translate innovation into clinical value. Today, BeOne operates across six continents in more than 45 markets and is supported by more than 1,200 oncology R&D professionals.
BeOne’s R&D platform has advanced more than 35 clinical-stage drug candidates, including three internally developed products that have received commercial approval, reaching more than 2 million patients worldwide.
Pipeline Highlights
BeOne continues to expand its global footprint through a portfolio of internally developed products, including:
- BTK Inhibitor: As the company’s first self-developed innovative drug, it holds a significant position in the global market (including Hong Kong), particularly in the field of B-cell malignancies.
- PD-1 Inhibitor: Launched in more than 50 markets worldwide, reaching 1.8 million people. In Hong Kong, it has been approved for six indications, including immunotherapy for lung, esophageal and gastric cancers.
- Next-Generation BCL-2 Inhibitor: Approved for certain lymphoma indications in Mainland China. It has been granted Priority Review by the U.S. Food and Drug Administration, and a marketing application has been submitted in the European Union.
Manufacturing Network Supporting Global Supply
BeOne maintains an integrated chain from R&D to manufacturing and commercialization, supported by production sites in the United States and China designed to help maintain a stable global supply:
- New Jersey, U.S.: A North America biologics hub integrating manufacturing and clinical R&D. The site spans 1.82 million square feet, including a dedicated 400,000-square-foot production facility.
- Suzhou, China (small molecule manufacturing): Supports clinical and commercial-scale production in accordance with applicable FDA, EMA and GMP requirements.
- Guangzhou, China (biologics and ADC manufacturing): A 1.3 million-square-foot facility supporting R&D and production of antibody-drug conjugates (ADCs) and serving as a supply hub for the Greater Bay Area, including Hong Kong.
BeOne has also been recognized by industry organizations for its innovation, including being named one of the “Top 10 Most Inventive” pharmaceutical companies by IDEA Pharma in 2025[1]. The company will continue to advance programs in hematologic malignancies and solid tumors, with Hong Kong serving as a strategic hub to support the delivery of innovative therapies globally.
1. 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma
This material is intended for the purpose of communicating disease-related knowledge and cutting-edge medical information to the public and is not intended for promotional or advertising purposes. It does not constitute a promotion or recommendation for any medication or treatment plan, nor can it serve as a substitute for the advice of medical and health professionals. If you have any questions, please consult a medical or health professional.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeOne undertakes no duty to update such information unless required by law.For BeOne’s newsroom, please visit www.beonemedicines.com
Hashtag: #BeOneMedicines
https://www.beonemedicines.com/
The issuer is solely responsible for the content of this announcement.
About BeOne Medicines
BeOne Medicines is a global oncology company domiciled in Switzerland, focused on discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is advancing a diverse pipeline of novel therapeutics through internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to improving access to medicines for more patients. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
About HKCT Business Awards 2026
Organized by the Hong Kong Commercial Times, the HKCT Business Awards is a representative annual event in the Hong Kong business community. It honors companies demonstrating excellence, innovation, and significant contributions to Hong Kong’s economy and society across dimensions including technological innovation and market competitiveness.
New boutique separates luxury brand collections across two dedicated spaces, giving collectors a more focused buying experience
SINGAPORE – Media OutReach Newswire – 12 May 2026 – Watchbook Singapore has opened a second boutique at Far East Plaza, separating its curated collections across two dedicated spaces on the same floor to give collectors a more focused buying experience.
The expansion allows Watchbook to organise its inventory by brand family. The main boutique at #03-139 focuses on Rolex, Patek Philippe, Audemars Piguet and Cartier. The new boutique at #03-55 features contemporary luxury watches including Tudor, Omega, Hublot and other brands.
“By giving each collection its own dedicated space, we can offer collectors a sharper, more personalised experience,” said Anson Toh, chief executive officer at Watchbook Singapore. “This expansion reflects the growing interest in both neo-vintage and modern luxury watches, and our commitment to serving collectors at every level.”
Watchbook enters this next phase as Singapore’s second-highest-reviewed watch dealer, with more than 2,400 verified Google reviews reflecting thousands of successful transactions. Both boutiques are backed by the company’s end-to-end model: in-house authentication, a dedicated service centre staffed by certified watchmakers, and curated inventory under one roof.
Far East Plaza is well-established as a destination for watch enthusiasts and luxury retailers in Singapore. The opening of a second boutique on the same floor reinforces Watchbook’s position at the centre of that community.
Boutique Details
Main boutique
14 Scotts Road,
#03-139 Far East Plaza,
Singapore 228213.
New boutique
14 Scotts Road,
#03-55 Far East Plaza,
Singapore 228213.
Hashtag: #watchbook #fareastplaza
https://watchbook.sg/
https://www.linkedin.com/company/watchbook-singapore/
https://www.facebook.com/watchbooksg/
https://www.instagram.com/watchbooksg/
The issuer is solely responsible for the content of this announcement.
Watchbook Singapore
Watchbook is Singapore’s Neo-Vintage Rolex Specialist and a trusted destination for authenticated pre-owned luxury watches. The company offers one of Singapore’s deepest curated selections of certified neo-vintage Rolex timepieces from the 1980s to 2000s, alongside a broader portfolio including Patek Philippe, Audemars Piguet, Cartier, Omega and more.
As an independent luxury watch dealer, Watchbook operates a fully in-house service centre staffed by certified watchmakers, delivering complete authentication, servicing and warranty support. Recognised as Singapore’s second-highest-reviewed watch dealer, Watchbook serves collectors and enthusiasts who value heritage, character and certified quality.
Short Courses Structured for Busy Professionals
For working adults who want targeted upskilling, SIM Academy’s course listing includes instructor-led programmes that are typically offered in short formats. The 1-day or 2-day course structure may appeal to professionals seeking to build capability while balancing work and personal commitments.
The topics covered reflect a mix of core workplace capabilities and emerging skill areas, including communication skills, cognitive skills, systems leadership, sustainability, as well as broader organisational and leadership competencies. Such short-format training has become a common feature within Singapore’s continuing education landscape, particularly among working adults seeking to remain competitive in a changing job market.
SkillsFuture Funded Training Courses
A number of SIM Academy’s professional development courses are eligible for SkillsFuture Credit and related funding schemes. These funding mechanisms are part of national efforts to encourage lifelong learning and support workforce transformation. The availability of funding-supported courses may lower barriers to participation for individuals and employers, particularly for those pursuing incremental skills upgrading.
Career Switch for mid‑career professionals
SIM Academy offers programmes under the SkillsFuture Career Transition Programme (SCTP). These programmes are designed for individuals considering a shift into new roles or sectors and typically run over 5-6 months. Programme structures may include a combination of classroom learning, practical projects and career support elements such as guidance on job search and career planning.
This reflects a broader trend in Singapore’s training ecosystem, where structured transition programmes are increasingly used to support workforce mobility and adaptation to new job roles.
Flexible Delivery Formats
SIM Academy’s programmes are delivered through a mix of in-person, online and blended learning formats. This allows participants to select learning modes that align with their schedules and professional commitments. Short courses are conducted throughout the year, primarily at SIM Management House, alongside digital learning options that support greater accessibility. Flexible delivery has become an increasingly important feature of professional education, particularly for working adults balancing training with full-time employment.
Part of a Broader Continuing Education Landscape
As industries continue to evolve, demand for continuous skills development remains a key focus within Singapore’s workforce strategy. Short courses, modular training and structured transition programmes are among the approaches adopted by training providers to meet these needs.
SIM Academy’s range of offerings includes shorter, skills-focused workshops and longer-duration programmes designed to support career transitions.
References
- SIM Academy: https://www.sim.edu.sg/professional-development/overview
- Courses offered by SIM Academy: https://www.sim.edu.sg/professional-development/courses/course-listing
- SkillsFuture Courses offered at SIM: https://www.sim.edu.sg/professional-development/courses/skillsfuture-courses
- SkillsFuture Career Transition Programme (SCTP): https://sctp.pd.sim.edu.sg
Hashtag: #SIMAcademy #SIMA
The issuer is solely responsible for the content of this announcement.
About SIM Academy
SIM Academy provides leading-edge professional development and enterprise solutions. SIM Academy offers over 300 executive and business programmes that help almost 10,000 professionals annually on average hone their competencies to drive business value and achieve peak personal and enterprise performance.
Our programmes encompass a comprehensive range of lifelong learning opportunities designed to empower professionals with the knowledge, skills, and competencies necessary to become effective change-makers and leaders in today’s volatile and uncertain business landscape.
For more information on SIM Academy, visit sim.edu.sg
Media OutReach
Patented Ingredients Help Malaysian Supplement Brands Stand Out as Wel-Bloom Bio-Tech Expands Market Presence
According to IMARC Group, the Malaysian dietary supplements sector is projected to grow at a CAGR of 4.68% through 2034.Amidst this expansion, Wel-Bloom Bio-Tech emphasizes the importance of leveraging high-barrier patented ingredients. For the beauty and wellness sector, the exclusive ingredient Wel-ROS6® utilizes the “Black Crystal Roselle,” a variety developed over nine years. Through a triple-patented micro-grinding technology, the total anthocyanin content reaches up to 17.7 times that of conventional roselle extracts.
To address the aging population’s needs, Wel-Bloom Bio-Tech also introduces Wel-EGT®, a high-purity ergothioneine extracted through a patented process. This ingredient serves as a core component for cognitive health supplements, offering 5 times the BCAA content of standard chicken essence to support anti-aging and neurological health.
Beyond ingredient innovation, Wel-Bloom’s patented Functional Jelly technology enables preservative-free supplements that maintain 97.8% active ingredient integrity. As an international CDMO and health supplement manufacturer certified under NSF-GMP and HALAL, Wel-Bloom Bio-Tech provides integrated services from R&D to production, empowering Malaysian partners to achieve differentiated positioning in the evolving wellness market.
Hashtag: #Welbloom
The issuer is solely responsible for the content of this announcement.
About Wel-Bloom Bio-Tech
Wel-Bloom is a globally recognized CDMO expert in the health food industry, dedicated to delivering innovative, one-stop solutions. Guided by forward-looking market insights and supported by robust R&D capabilities, Wel-Bloom empowers clients to develop highly competitive, differentiated health food products.
For partnership opportunities and functional ingredient solutions, visit https://welbloom.com/ or search for Wel-Bloom online.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn